MedTrace Logo

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-05-09

No results posted yet for this study

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytomegalovirus infection that has not responded to therapy.

Conditions

Interventions

BIOLOGICAL

cytomegalovirus pp65-specific cytotoxic T lymphocytes

GENETIC

polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

OTHER

flow cytometry

OTHER

immunologic technique

Sponsors & Collaborators

  • Penn State University

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Kenneth G. Lucas, MD · Milton S. Hershey Medical Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509691 on ClinicalTrials.gov